NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors Baxter International, Inc. (NYSE: BAX) and Molina Healthcare, Inc. (NYSE: MOH) on behalf of long-term stockholders. More information about each potential case can be found at the link provided. Baxter International, Inc. (NYSE: BAX) Bragar Eagel & Squire is investigating certain officers and directors of Baxter International, Inc. foll ...

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Baxter International, Inc. ("Baxter International, Inc." or the "Company") (NYSE: BAX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Baxter International, Inc. investors who were adversely affected by alleged securities fraud between February 23, 2022 and October 29, 2025. Follow the link below to get more information and be contacted by a member of our team: htt ...

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (NYSE: BAX) between February 23, 2022 and July 30, 2025, both dates inclusive (the “Class Period”), of the important December 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased Baxter common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Baxter (BAX) To Contact Him Directly To Discuss Their Options If you purchased Baxter common stock between February 23, 2022 and October 29, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel ...

Key Takeaways Data at ASHP 2025 shows BAX EMR integration reduced safety alerts and improved IV infusion setup.BAX data shows hard limit alerts fell 50.3% and soft limits dropped 30.4% across UTMB hospitals.BAX auto-programming cut median setup time from 10 to 4 seconds and sped alert resolution.Baxter International Inc. (BAX) recently shared real-world data at the American Society of Health-System Pharmacists (“ASHP”) 2025 Midyear Clinical Meeting, highlighting the benefits of integrating smart infusion pu ...

To learn more about the Baxter International class action, go to www.faruqilaw.com/BAX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. The true extent of Defendants' fraud was revealed on July 31, 2025, when the Company announced that it had decided to "voluntarily and temporarily pause shipments and planned installations of the Novum LVP†and that the Company was "unable to currently commit to an exact ...

Core Insights - The article highlights the acceleration of business development (BD) activities in the medical device sector from September to November 2025, with a total of 58 transactions identified across various subfields, including cardiovascular, nuclear medicine, and AI-enabled devices [2][3][4]. Group 1: Mergers and Acquisitions - Mergers and acquisitions have become a prominent form of BD, with companies leveraging capital control and product integration for rapid market positioning [7][8]. - Notable acquisitions include HeartLink's $680 million all-stock acquisition of Micro-Invasive Cardiology, enhancing its structural heart disease and rhythm management capabilities [7]. - Hua'an Zhonghui's acquisition of Bangni Medical marks its entry into the absorbable suture market, indicating a shift in surgical instrument competition towards material innovation [7]. Group 2: Strategic Collaborations - Strategic partnerships have been formed during the China International Import Expo, with companies like Shanghai Pharmaceuticals collaborating with international giants such as Boston Scientific and Medtronic to enhance their supply chain and academic promotion systems [7][8]. - The collaboration between GuoYao Medical and BDI Medical aims to deepen market penetration in the biomedicine and medical device sectors, focusing on compliance and distribution channel construction [13]. Group 3: Cross-Border Cooperation - Cross-border transactions have become more active, with foreign companies establishing local R&D and production systems in China, while domestic firms are exporting their solutions globally [9][10]. - The partnership between Trasis SA and Beijing Pait Biotechnology to establish a joint venture reflects a trend towards localized production and phased integration in the Chinese market [12]. Group 4: Ecosystem Building and Channel Expansion - The integration of supply chains and ecosystem building is a key theme, with companies focusing on collaborative agreements to enhance their market presence [11][15]. - The collaboration between Baxter and Neusoft Medical aims to create a comprehensive surgical solution by integrating their respective technologies [12]. Group 5: AI and Smart Healthcare - AI and data-driven approaches are becoming central to BD collaborations, with companies increasingly focusing on smart healthcare solutions [16][17]. - The partnership between Kefu Medical and Tencent Cloud to develop AI-powered hearing aids exemplifies the trend of integrating technology into healthcare products [21]. Group 6: Research and Diagnostic Synergy - The frequency of research-oriented collaborations is rising, indicating a shift from manufacturing-driven to research-driven industry dynamics [18][19]. - The collaboration between BGI and Infinera to enhance clinical applications of sequencing technology highlights the growing importance of research in driving innovation in the medical device sector [21].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of false and misleading statements regarding the Novum LVP medical device, which has been linked to serious malfunctions and patient risks [2][4]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses in Baxter between February 23, 2022, and October 29, 2025, to discuss their legal rights [1]. - There is a deadline of December 15, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Baxter [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs and oversees the litigation on behalf of the class [6]. Group 2: Allegations Against Baxter - The complaint alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which caused malfunctions that could lead to serious injury or death [4]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of product withdrawal from the market [4]. - The company's statements regarding the safety and efficacy of the Novum LVPs were claimed to be materially false and misleading [4]. Group 3: Impact on Stock Performance - The extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary pause in shipments and installations of the Novum LVP, resulting in a 22.4% drop in stock price, closing at $21.76 [5].

Core Points - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered systemic defects leading to serious patient risks [3][7] - The lawsuit covers individuals who purchased Baxter common stock between February 23, 2022, and October 29, 2025, with a deadline of December 15, 2025, for investors to apply as lead plaintiffs [7] Allegation Details - The complaint claims that Baxter failed to disclose critical information about the Novum LVP, including systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, which posed risks of serious injury or death to patients [3] - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures, leading to continued harm [3] - The lawsuit suggests that Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were materially false and misleading [3] Next Steps - Investors who suffered losses and wish to learn more about the claims or have questions are encouraged to contact the law firm Bragar Eagel & Squire, P.C. for further information [4] - The firm emphasizes that there is no cost or obligation for investors to inquire about their rights [4] About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in complex litigation across state and federal courts [5]

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming December 15, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Baxter International, Inc. ("Baxter" or the "Company") (NYSE: BAX) securities between February 23, 2022 and October 29, 2025,inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO LOST MONEY ON BAXTER (BAX), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD LA ...